Page last updated: 2024-11-06

distearoyl phosphatidylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

distearoyl phosphatidylglycerol: a surface-active agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

distearoyl phosphatidylglycerol : A phosphatidylglycerol in which the phosphatidyl acyl groups are both stearoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65145
CHEBI ID61056
SCHEMBL ID21434493
MeSH IDM0224147

Synonyms (33)

Synonym
distearoyl ppg
distearoyl phosphatidylglycerol
dspg
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate
c18:0 pg
3-{[(2,3-dihydroxypropoxy)(hydroxy)phosphoryl]oxy}propane-1,2-diyl dioctadecanoate
octadecanoic acid, 1-((((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl ester
distearoylphoshatidylglycerol
phosphoric acid mono-(2,3-bis-stearoyloxy-propyl ester)
dioctanoylphosphatididylglycerol
4537-78-4
1,2-di-o-octadecanoyl-rac-3-glycerophosphate
CHEBI:61056
1,2-di-o-stearoyl-rac-3-glycerophosphate
FT-0650998
4271za8wxo ,
unii-4271za8wxo
octadecanoic acid, 1,1'-(1-((((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl) ester
dspg, dl-
distearoylphosphatidylglycerol
stearin, 1,2-di-, 1-glycerophosphate
dspg, (+/-)-
distearoylphosphatidylglycerol, dl-
stearic acid, 3-hydroxypropylene ester hydrogen 2,3-dihydroxypropyl phosphate
SCHEMBL21434493
FVJZSBGHRPJMMA-UHFFFAOYSA-N
Q27130594
3-{[(2,3-dihydroxypropoxy)(hydroxy)phosphoryl]oxy}-2-(octadecanoyloxy)propyl octadecanoate
DTXSID30963376
1,2-distearoyl-sn-glycero-3-phosphorylglycerol
3-(((2,3-dihydroxypropoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl distearate
PD047468
pg 18:0_18:0

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The first dose resulted in a reduction in the circulation half-life of the second dose."( Accelerated clearance of a second injection of PEGylated liposomes in mice.
Ichihara, M; Ichikawa, T; Irimura, K; Ishida, T; Kiwada, H; Masuda, K, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
"Compared to conventional parenteral formulations injectable depot formulations, owing to a sustained drug release, offer several advantages, such as a reduced dosing frequency - and consequent improved compliance - or a predictable release profile."( Study on the in situ aggregation of liposomes with negatively charged phospholipids for use as injectable depot formulation.
Luciani, P; Rahnfeld, L; Steiniger, F; Thamm, J; van Hoogevest, P, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphatidylglycerolA glycerophosphoglycerol that is glycerol in which the hydrogen of one of the primary hydroxy groups has been replaced by a phosphatidyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (12.50)18.2507
2000's17 (42.50)29.6817
2010's17 (42.50)24.3611
2020's1 (2.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.62 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.44%)6.00%
Case Studies1 (2.44%)4.05%
Observational0 (0.00%)0.25%
Other39 (95.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]